Leadership

Overview

The Pancreatic Cancer Collective reflects the strategic partnership of these two leading cancer research organizations: Stand Up To Cancer and Lustgarten Foundation. Leadership of the Collective comprises the scientific and lay leadership of these collaborating organizations.

Scientific Leadership

Dr. Phillip A. Sharp, PhD

Dr. Phillip A. Sharp, a Nobel Laureate, is institute professor at the Massachusetts Institute of Technology (MIT) and its Koch Institute for Integrated Cancer Research. Dr. Sharp chairs the SU2C Scientific Advisory Committee comprising some two dozen of the most esteemed cancer researchers in the US and Canada. The SAC and its committees provide expert oversight for the scientific direction of the SU2C research portfolio, selection of grants for funding, and rigorous semi-annual review of active grants. Dr. Sharp drives SU2C’s continuous search for innovation to produce better outcomes for patients.

David Tuveson, MD, PhD

David Tuveson, MD, PhD is the Chief Scientist for Lustgarten Foundation. Dr. Tuveson is the Director of the Cold Spring Harbor Laboratory (CSHL) Cancer Center, the Roy J. Zuckerberg Professor and oversees Lustgarten Foundation’s Dedicated Research Laboratory at Cold Spring Harbor Laboratory. Dr. Tuveson is responsible for the scientific and research functions of the Foundation. Dr. Tuveson also serves as a member of the SU2C Scientific Advisory Committee.

Executive Leadership

Kerri Kaplan

Kerri Kaplan is the President and CEO of Lustgarten Foundation for Pancreatic Cancer Research, America’s largest private foundation dedicated to funding pancreatic cancer research. Ms. Kaplan oversees all aspects of the Lustgarten Foundation’s operational activities, including major fundraising initiatives, patient outreach, and the Foundation’s in-depth research portfolio.